Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

NCT05008224 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

Classical Hodgkin Lymphoma

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Doxorubicin
DRUG: Vinblastine
DRUG: Dacarbazine
DRUG: Bleomycin
DRUG: Etoposide
DRUG: Cyclophosphamide
DRUG: Vincristine
DRUG: Procarbazine
DRUG: Prednisone

Sponsor

Merck Sharp & Dohme LLC